权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Study on hepatitis C virus new genotypes in Southeast Asia

东南亚丙型肝炎病毒新基因型研究

基本信息

批准号：
08041176
负责人：
HOTTA Hak
金额：
$ 1.54万
依托单位：
Kobe University School of Medicine
依托单位国家：
日本
项目类别：
Grant-in-Aid for international Scientific Research
财政年份：
1996
资助国家：
日本
起止时间：
1996 至无数据
项目状态：
已结题

来源：
https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-08041176/
关键词：
hepatitis C virus genotype seroepidemiology molecular epidemiology Southeast Asia lndonesia Thailand Philippines

项目摘要

Sero- and molecular epidemiological analyzes of hepatitis C virus (HCV) in Surabaya, lndonesia, were performed. Prevalence of anti-HCV antibodies was 2.3% in healthy blood donors. The prevalence was 5-times higher in those with liver dysfunction than in those without. HCV subtype 2a (HCV-2a) was most common (52%) among HCV isolates from blood donors. On the other hand, HCV-1a, -1b and -1d were associated with elevation of serum ALT levels in blood donors, suggesting a possibly more pathogenic feature of those subtypes than HCV-2a. These results would be beneficial to control posttransfusion hepatitis. In patients on maintenance hemodialysis, the prevalence of anti-HCV antibodies was 62.3%. HCV-1a and -1b (each 31%) were among the most common subtypes in this group. These results suggest an increased risk of HCV infection in hemodialysis, where preventive measures should be taken. In contrast to the case with blood donors, there was no significant difference in subtype prevalence between hemodialyzed patients with liver dysfunction and those without. Impaired immune responses of hemodialyzed patients might be responsible for the apparently decreased hepatocytic injury caused by HCV infection. In patients with HCC,the prevalence of anti-HCV antibodies was 64.7%. HCV-1b (57%) was the most common subtype, followed by HCV-1d (19%) and -2a (5%). Subtype prevalence was not different between HCC patients with advanced liver cirrhosis and those without. A novel subtype (HCV-3g) was identified, although its prevalence was rather low.Hepatitis G virus (HGV) infection in Chiang Mai, Thailand, was also studied. The prevalence of HGV RNA was 32%, 25%, 10% and 1% in intravenous drug users, hemodialyzed patients, chronic liver disease patients and blood donors, respectively. The prevalence was significantly higher in individuals with HCV infection (24%) than in those without (5%).

对印度尼西亚泗水地区丙型肝炎病毒（HCV）进行了血清和分子流行病学分析。在健康的献血者中，抗hcv抗体的患病率为2.3%。有肝功能障碍者的患病率是无肝功能障碍者的5倍。HCV亚型2a （HCV-2a）在献血者分离的HCV中最常见（52%）。另一方面，HCV-1a、-1b和-1d与献血者血清ALT水平升高相关，提示这些亚型可能比HCV-2a更具致病性。这些结果将有利于输血后肝炎的控制。维持性血液透析患者中，抗hcv抗体的患病率为62.3%。HCV-1a和-1b（各占31%）是该组中最常见的亚型。这些结果提示血液透析患者丙型肝炎病毒感染风险增加，应采取预防措施。与献血者相比，有肝功能障碍的血液透析患者和没有肝功能障碍的血液透析患者在亚型患病率上没有显著差异。血液透析患者的免疫反应受损可能是HCV感染引起的肝细胞损伤明显减轻的原因。在HCC患者中，抗hcv抗体的患病率为64.7%。HCV-1b（57%）是最常见的亚型，其次是HCV-1d（19%）和-2a（5%）。晚期肝硬化HCC患者与非晚期肝硬化HCC患者的亚型患病率无差异。发现了一种新的亚型（HCV-3g），尽管其患病率相当低。在泰国清迈也研究了G型肝炎病毒（HGV）感染。静脉吸毒者、血液透析患者、慢性肝病患者和献血者中HGV RNA的患病率分别为32%、25%、10%和1%。HCV感染者的患病率（24%）明显高于未感染者（5%）。